English
简体中文
Total: £ 56.28
Published Date: 2025-03-25 | Pages: 92 | Tables: 92 | Pharma & Healthcare
The global market for Follicular Lymphoma Drugs was valued at US$ 1972 million in the year 2024 and is projected to reach a revised size of US$ 3227 million by 2031, growing at a CAGR of 7.4% during the forecast period.
Follicular lymphoma is a cancer that affects white blood cells called lymphocytes. There are two types of lymphomas: Hodgkin's and non-Hodgkin's, based on the kind of white blood cell they affect. Follicular lymphoma is a non-Hodgkin's lymphoma.Drugs for Follicular lymphoma are Anti-CD20 mAbs, Chemotherapy Agents, Kinase Inhibitor, etc.
The follicular lymphoma drugs market is primarily driven by the increasing prevalence of follicular lymphoma (FL), a common and slow-growing form of non-Hodgkin lymphoma. As the global population ages, the incidence of FL is expected to rise, which boosts demand for effective treatments. Additionally, recent advancements in targeted therapies, including monoclonal antibodies like rituximab and the development of novel small molecules, have significantly improved patient outcomes and survival rates. The growing adoption of combination therapies, such as chemotherapy paired with targeted treatments or immunotherapies, has further expanded treatment options and contributed to the market's growth. The emergence of personalized medicine also enhances the potential for more tailored, effective therapies.
On the other hand, the follicular lymphoma drugs market faces challenges, including the high cost of cutting-edge therapies. Treatments such as CAR-T cell therapy and novel biologics, while effective, can be expensive and limit patient access, particularly in lower-income regions. Additionally, although FL is typically slow-growing, it is also highly recurrent, requiring long-term management and monitoring, which can strain healthcare systems. The risk of resistance to existing therapies, along with concerns over the long-term side effects of certain treatments, further complicates the landscape. Regulatory hurdles for the approval of new drugs, along with the need for ongoing research into optimizing treatment regimens, present further challenges in meeting the diverse needs of FL patients.
Global core follicular lymphoma drugs players include Roche, Teva and Bayer etc. The Top3 companies hold a share about 57%. North America is the largest market, with a share about 58%, followed by Europe and Asia Pacific with the share about 21% and 20%.
This report aims to provide a comprehensive presentation of the global market for Follicular Lymphoma Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Follicular Lymphoma Drugs.
The Follicular Lymphoma Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Follicular Lymphoma Drugs market comprehensively. Regional market sizes, concerning products by Type, by Administration Route, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Follicular Lymphoma Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Administration Route, and by regions.
Market Segmentation
By Company
Roche
Gilead Sciences
Beigene
Bayer
Secura Bio
Epizyme
Eisai
Acrotech Biopharma
Teva
Eagle Pharmaceuticals
MundiPharma
Pfizer
Novartis
Bristol-Myers Squibb
JW Therapeutics
FOSUNKite
Segment by Type
Anti-CD20 mAbs
Chemotherapy Agents
Kinase Inhibitor
Others
Segment by Administration Route
Injection
Oral
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Administration Route, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Follicular Lymphoma Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Administration Route, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Follicular Lymphoma Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Anti-CD20 mAbs
1.2.3 Chemotherapy Agents
1.2.4 Kinase Inhibitor
1.2.5 Others
1.3 Market by Administration Route
1.3.1 Global Follicular Lymphoma Drugs Market Growth by Administration Route: 2020 VS 2024 VS 2031
1.3.2 Injection
1.3.3 Oral
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Follicular Lymphoma Drugs Market Perspective (2020-2031)
2.2 Global Follicular Lymphoma Drugs Growth Trends by Region
2.2.1 Global Follicular Lymphoma Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Follicular Lymphoma Drugs Historic Market Size by Region (2020-2025)
2.2.3 Follicular Lymphoma Drugs Forecasted Market Size by Region (2026-2031)
2.3 Follicular Lymphoma Drugs Market Dynamics
2.3.1 Follicular Lymphoma Drugs Industry Trends
2.3.2 Follicular Lymphoma Drugs Market Drivers
2.3.3 Follicular Lymphoma Drugs Market Challenges
2.3.4 Follicular Lymphoma Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Follicular Lymphoma Drugs Players by Revenue
3.1.1 Global Top Follicular Lymphoma Drugs Players by Revenue (2020-2025)
3.1.2 Global Follicular Lymphoma Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Follicular Lymphoma Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Follicular Lymphoma Drugs Revenue
3.4 Global Follicular Lymphoma Drugs Market Concentration Ratio
3.4.1 Global Follicular Lymphoma Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Follicular Lymphoma Drugs Revenue in 2024
3.5 Global Key Players of Follicular Lymphoma Drugs Head office and Area Served
3.6 Global Key Players of Follicular Lymphoma Drugs, Product and Application
3.7 Global Key Players of Follicular Lymphoma Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Follicular Lymphoma Drugs Breakdown Data by Type
4.1 Global Follicular Lymphoma Drugs Historic Market Size by Type (2020-2025)
4.2 Global Follicular Lymphoma Drugs Forecasted Market Size by Type (2026-2031)
5 Follicular Lymphoma Drugs Breakdown Data by Administration Route
5.1 Global Follicular Lymphoma Drugs Historic Market Size by Administration Route (2020-2025)
5.2 Global Follicular Lymphoma Drugs Forecasted Market Size by Administration Route (2026-2031)
6 North America
6.1 North America Follicular Lymphoma Drugs Market Size (2020-2031)
6.2 North America Follicular Lymphoma Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Follicular Lymphoma Drugs Market Size by Country (2020-2025)
6.4 North America Follicular Lymphoma Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Follicular Lymphoma Drugs Market Size (2020-2031)
7.2 Europe Follicular Lymphoma Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Follicular Lymphoma Drugs Market Size by Country (2020-2025)
7.4 Europe Follicular Lymphoma Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Follicular Lymphoma Drugs Market Size (2020-2031)
8.2 Asia-Pacific Follicular Lymphoma Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Follicular Lymphoma Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Follicular Lymphoma Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Follicular Lymphoma Drugs Market Size (2020-2031)
9.2 Latin America Follicular Lymphoma Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Follicular Lymphoma Drugs Market Size by Country (2020-2025)
9.4 Latin America Follicular Lymphoma Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Follicular Lymphoma Drugs Market Size (2020-2031)
10.2 Middle East & Africa Follicular Lymphoma Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Follicular Lymphoma Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Follicular Lymphoma Drugs Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Follicular Lymphoma Drugs Introduction
11.1.4 Roche Revenue in Follicular Lymphoma Drugs Business (2020-2025)
11.1.5 Roche Recent Development
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Details
11.2.2 Gilead Sciences Business Overview
11.2.3 Gilead Sciences Follicular Lymphoma Drugs Introduction
11.2.4 Gilead Sciences Revenue in Follicular Lymphoma Drugs Business (2020-2025)
11.2.5 Gilead Sciences Recent Development
11.3 TG Therapeutics
11.3.1 TG Therapeutics Company Details
11.3.2 TG Therapeutics Business Overview
11.3.3 TG Therapeutics Follicular Lymphoma Drugs Introduction
11.3.4 TG Therapeutics Revenue in Follicular Lymphoma Drugs Business (2020-2025)
11.3.5 TG Therapeutics Recent Development
11.4 Bayer
11.4.1 Bayer Company Details
11.4.2 Bayer Business Overview
11.4.3 Bayer Follicular Lymphoma Drugs Introduction
11.4.4 Bayer Revenue in Follicular Lymphoma Drugs Business (2020-2025)
11.4.5 Bayer Recent Development
11.5 Secura Bio
11.5.1 Secura Bio Company Details
11.5.2 Secura Bio Business Overview
11.5.3 Secura Bio Follicular Lymphoma Drugs Introduction
11.5.4 Secura Bio Revenue in Follicular Lymphoma Drugs Business (2020-2025)
11.5.5 Secura Bio Recent Development
11.6 Epizyme
11.6.1 Epizyme Company Details
11.6.2 Epizyme Business Overview
11.6.3 Epizyme Follicular Lymphoma Drugs Introduction
11.6.4 Epizyme Revenue in Follicular Lymphoma Drugs Business (2020-2025)
11.6.5 Epizyme Recent Development
11.7 Eisai
11.7.1 Eisai Company Details
11.7.2 Eisai Business Overview
11.7.3 Eisai Follicular Lymphoma Drugs Introduction
11.7.4 Eisai Revenue in Follicular Lymphoma Drugs Business (2020-2025)
11.7.5 Eisai Recent Development
11.8 Acrotech Biopharma
11.8.1 Acrotech Biopharma Company Details
11.8.2 Acrotech Biopharma Business Overview
11.8.3 Acrotech Biopharma Follicular Lymphoma Drugs Introduction
11.8.4 Acrotech Biopharma Revenue in Follicular Lymphoma Drugs Business (2020-2025)
11.8.5 Acrotech Biopharma Recent Development
11.9 Teva
11.9.1 Teva Company Details
11.9.2 Teva Business Overview
11.9.3 Teva Follicular Lymphoma Drugs Introduction
11.9.4 Teva Revenue in Follicular Lymphoma Drugs Business (2020-2025)
11.9.5 Teva Recent Development
11.10 Eagle Pharmaceuticals
11.10.1 Eagle Pharmaceuticals Company Details
11.10.2 Eagle Pharmaceuticals Business Overview
11.10.3 Eagle Pharmaceuticals Follicular Lymphoma Drugs Introduction
11.10.4 Eagle Pharmaceuticals Revenue in Follicular Lymphoma Drugs Business (2020-2025)
11.10.5 Eagle Pharmaceuticals Recent Development
11.11 MundiPharma
11.11.1 MundiPharma Company Details
11.11.2 MundiPharma Business Overview
11.11.3 MundiPharma Follicular Lymphoma Drugs Introduction
11.11.4 MundiPharma Revenue in Follicular Lymphoma Drugs Business (2020-2025)
11.11.5 MundiPharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Follicular Lymphoma Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Anti-CD20 mAbs
Table 3. Key Players of Chemotherapy Agents
Table 4. Key Players of Kinase Inhibitor
Table 5. Key Players of Others
Table 6. Global Follicular Lymphoma Drugs Market Size Growth by Administration Route (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Follicular Lymphoma Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Follicular Lymphoma Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Follicular Lymphoma Drugs Market Share by Region (2020-2025)
Table 10. Global Follicular Lymphoma Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Follicular Lymphoma Drugs Market Share by Region (2026-2031)
Table 12. Follicular Lymphoma Drugs Market Trends
Table 13. Follicular Lymphoma Drugs Market Drivers
Table 14. Follicular Lymphoma Drugs Market Challenges
Table 15. Follicular Lymphoma Drugs Market Restraints
Table 16. Global Follicular Lymphoma Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Follicular Lymphoma Drugs Market Share by Players (2020-2025)
Table 18. Global Top Follicular Lymphoma Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Follicular Lymphoma Drugs as of 2024)
Table 19. Ranking of Global Top Follicular Lymphoma Drugs Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Follicular Lymphoma Drugs Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Follicular Lymphoma Drugs, Headquarters and Area Served
Table 22. Global Key Players of Follicular Lymphoma Drugs, Product and Application
Table 23. Global Key Players of Follicular Lymphoma Drugs, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Follicular Lymphoma Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Follicular Lymphoma Drugs Revenue Market Share by Type (2020-2025)
Table 27. Global Follicular Lymphoma Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Follicular Lymphoma Drugs Revenue Market Share by Type (2026-2031)
Table 29. Global Follicular Lymphoma Drugs Market Size by Administration Route (2020-2025) & (US$ Million)
Table 30. Global Follicular Lymphoma Drugs Revenue Market Share by Administration Route (2020-2025)
Table 31. Global Follicular Lymphoma Drugs Forecasted Market Size by Administration Route (2026-2031) & (US$ Million)
Table 32. Global Follicular Lymphoma Drugs Revenue Market Share by Administration Route (2026-2031)
Table 33. North America Follicular Lymphoma Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Follicular Lymphoma Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Follicular Lymphoma Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Follicular Lymphoma Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Follicular Lymphoma Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Follicular Lymphoma Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Follicular Lymphoma Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Follicular Lymphoma Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Follicular Lymphoma Drugs Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Follicular Lymphoma Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Follicular Lymphoma Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Follicular Lymphoma Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Follicular Lymphoma Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Follicular Lymphoma Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Follicular Lymphoma Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 48. Roche Company Details
Table 49. Roche Business Overview
Table 50. Roche Follicular Lymphoma Drugs Product
Table 51. Roche Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)
Table 52. Roche Recent Development
Table 53. Gilead Sciences Company Details
Table 54. Gilead Sciences Business Overview
Table 55. Gilead Sciences Follicular Lymphoma Drugs Product
Table 56. Gilead Sciences Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)
Table 57. Gilead Sciences Recent Development
Table 58. TG Therapeutics Company Details
Table 59. TG Therapeutics Business Overview
Table 60. TG Therapeutics Follicular Lymphoma Drugs Product
Table 61. TG Therapeutics Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)
Table 62. TG Therapeutics Recent Development
Table 63. Bayer Company Details
Table 64. Bayer Business Overview
Table 65. Bayer Follicular Lymphoma Drugs Product
Table 66. Bayer Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)
Table 67. Bayer Recent Development
Table 68. Secura Bio Company Details
Table 69. Secura Bio Business Overview
Table 70. Secura Bio Follicular Lymphoma Drugs Product
Table 71. Secura Bio Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)
Table 72. Secura Bio Recent Development
Table 73. Epizyme Company Details
Table 74. Epizyme Business Overview
Table 75. Epizyme Follicular Lymphoma Drugs Product
Table 76. Epizyme Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)
Table 77. Epizyme Recent Development
Table 78. Eisai Company Details
Table 79. Eisai Business Overview
Table 80. Eisai Follicular Lymphoma Drugs Product
Table 81. Eisai Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)
Table 82. Eisai Recent Development
Table 83. Acrotech Biopharma Company Details
Table 84. Acrotech Biopharma Business Overview
Table 85. Acrotech Biopharma Follicular Lymphoma Drugs Product
Table 86. Acrotech Biopharma Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)
Table 87. Acrotech Biopharma Recent Development
Table 88. Teva Company Details
Table 89. Teva Business Overview
Table 90. Teva Follicular Lymphoma Drugs Product
Table 91. Teva Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)
Table 92. Teva Recent Development
Table 93. Eagle Pharmaceuticals Company Details
Table 94. Eagle Pharmaceuticals Business Overview
Table 95. Eagle Pharmaceuticals Follicular Lymphoma Drugs Product
Table 96. Eagle Pharmaceuticals Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)
Table 97. Eagle Pharmaceuticals Recent Development
Table 98. MundiPharma Company Details
Table 99. MundiPharma Business Overview
Table 100. MundiPharma Follicular Lymphoma Drugs Product
Table 101. MundiPharma Revenue in Follicular Lymphoma Drugs Business (2020-2025) & (US$ Million)
Table 102. MundiPharma Recent Development
Table 103. Research Programs/Design for This Report
Table 104. Key Data Information from Secondary Sources
Table 105. Key Data Information from Primary Sources
Table 106. Authors List of This Report
List of Figures
Figure 1. Follicular Lymphoma Drugs Picture
Figure 2. Global Follicular Lymphoma Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Follicular Lymphoma Drugs Market Share by Type: 2024 VS 2031
Figure 4. Anti-CD20 mAbs Features
Figure 5. Chemotherapy Agents Features
Figure 6. Kinase Inhibitor Features
Figure 7. Others Features
Figure 8. Global Follicular Lymphoma Drugs Market Size by Administration Route (2020-2031) & (US$ Million)
Figure 9. Global Follicular Lymphoma Drugs Market Share by Administration Route: 2024 VS 2031
Figure 10. Injection Case Studies
Figure 11. Oral Case Studies
Figure 12. Follicular Lymphoma Drugs Report Years Considered
Figure 13. Global Follicular Lymphoma Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 14. Global Follicular Lymphoma Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Follicular Lymphoma Drugs Market Share by Region: 2024 VS 2031
Figure 16. Global Follicular Lymphoma Drugs Market Share by Players in 2024
Figure 17. Global Top Follicular Lymphoma Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Follicular Lymphoma Drugs as of 2024)
Figure 18. The Top 10 and 5 Players Market Share by Follicular Lymphoma Drugs Revenue in 2024
Figure 19. North America Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. North America Follicular Lymphoma Drugs Market Share by Country (2020-2031)
Figure 21. United States Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Canada Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Follicular Lymphoma Drugs Market Share by Country (2020-2031)
Figure 25. Germany Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. France Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. U.K. Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Italy Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Russia Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Nordic Countries Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Follicular Lymphoma Drugs Market Share by Region (2020-2031)
Figure 33. China Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Japan Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. South Korea Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Southeast Asia Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. India Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Australia Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Follicular Lymphoma Drugs Market Share by Country (2020-2031)
Figure 41. Mexico Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Brazil Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Follicular Lymphoma Drugs Market Share by Country (2020-2031)
Figure 45. Turkey Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Saudi Arabia Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. UAE Follicular Lymphoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Roche Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)
Figure 49. Gilead Sciences Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)
Figure 50. TG Therapeutics Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)
Figure 51. Bayer Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)
Figure 52. Secura Bio Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)
Figure 53. Epizyme Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)
Figure 54. Eisai Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)
Figure 55. Acrotech Biopharma Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)
Figure 56. Teva Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)
Figure 57. Eagle Pharmaceuticals Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)
Figure 58. MundiPharma Revenue Growth Rate in Follicular Lymphoma Drugs Business (2020-2025)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
